Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Recommendation of “Moderate Buy” by Analysts

by · The Cerbat Gem

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) have received an average rating of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $395.00.

MEDP has been the subject of several recent analyst reports. William Blair reiterated an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and reduced their target price for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. Guggenheim decreased their target price on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a report on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft cut their price target on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a report on Wednesday, July 24th. Finally, TD Cowen lowered their price target on shares of Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th.

View Our Latest Research Report on MEDP

Medpace Stock Up 1.0 %

NASDAQ MEDP opened at $344.71 on Friday. The firm’s 50 day moving average is $360.65 and its 200-day moving average is $385.97. The company has a market capitalization of $10.69 billion, a PE ratio of 32.43, a price-to-earnings-growth ratio of 1.77 and a beta of 1.35. Medpace has a 12-month low of $227.21 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The firm had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same period last year, the company earned $1.93 earnings per share. The business’s revenue was up 14.6% compared to the same quarter last year. As a group, sell-side analysts expect that Medpace will post 11.64 EPS for the current year.

Hedge Funds Weigh In On Medpace

A number of institutional investors have recently added to or reduced their stakes in the stock. Rise Advisors LLC acquired a new position in shares of Medpace during the first quarter worth $27,000. Mather Group LLC. purchased a new stake in Medpace in the 1st quarter valued at $28,000. Fidelis Capital Partners LLC bought a new position in shares of Medpace during the 1st quarter worth approximately $31,000. J.Safra Asset Management Corp raised its stake in Medpace by 87.0% in the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares in the last quarter. Finally, DT Investment Partners LLC purchased a new stake in Medpace during the second quarter valued at about $41,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

(Get Free Report

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Read More